Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Peptide Drug Discovery Market Expected to Grow at a 11.3% CAGR from 2024-2031| Exclusive Report by InsightAce Analytic

InsightAce Analytic Logo

News provided by

InsightAce Analytic Pvt. Ltd

Jun 06, 2024, 10:01 ET

Share this article

Share toX

Share this article

Share toX

JERSEY CITY, N.J., June 6, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Peptide Drug Discovery Market- (By Type Of Product (Synthetic Peptides, Biological And Recombinant Peptides And Macrocycles), Drug Discovery Steps (Target Identification And Validation, Hit Identification, Lead Generation And Lead Optimization), Therapeutic Area (Oncological Disorders, Metabolic Disorders, Cardiovascular Disorders, Infectious Disorders, Urological Disorders, Endocrine Disorders, CNS Disorders), Company Size (Small, Mid-Sized And Large & Very Large Companies)), By Region, Trends, Industry Competition Analysis, Revenue And Forecast To 2031."

According to the latest research by InsightAce Analytic, the Peptide Drug Discovery Market is valued at US$ 704.9 Mn in 2023, and it is expected to reach US$ 1,633.9 Mn by 2031, with a CAGR of 11.3% during the forecast period of 2024-2031.

Peptide drugs have emerged as a promising class of therapeutic agents, due to their high specificity and low toxicity to target specific biological pathways. The process of peptide drug discovery involves a multifaceted approach, integrating advances in chemistry, biology, and computational methods.

Recent breakthroughs in design, synthesis, and structure-property relationship analysis have propelled the development of innovative therapies for various diseases, including cancer, metabolic disorders, and neurological conditions. This multidisciplinary effort has enabled the creation of peptides that interact with specific biological targets such as receptors, enzymes, or proteins, offering a level of precision unmatched by traditional small molecule or biological therapies.

Download Free Report Sample Pages: https://www.insightaceanalytic.com/request-sample/2510 

The significance of peptide drug discovery lies in its potential to tackle complex diseases that present challenges for conventional treatments. Peptides can be tailored to modulate protein-protein interactions, regulate gene expression, and target specific biological pathways. Their versatility extends to acting as agonists or antagonists for receptors, inhibitors of enzymes, and even vehicles for targeted drug delivery. This diverse application landscape positions peptide-based therapeutics as game-changers in the treatment landscape, offering not only enhanced efficacy but also improved safety profiles and patient outcomes across a wide spectrum of medical conditions, from chronic diseases like diabetes and cancer to neurodegenerative disorders such as Alzheimer's and Parkinson's.

List of Prominent Players in the Peptide Drug Discovery Market:

  • GenScript
  • JPT Peptide Technologies
  • CPC Scientific
  • IRBM
  • Creative Peptides
  • Pepscan
  • Peptides and Macrocycle Drug Discovery Platform Providers
  • RA Pharmaceuticals
  • Pepticom
  • PeptiDream
  • Creative Biolabs
  • MeSCue-Janusys

Peptide Drug Discovery Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2022

USD 704.9 Mn

Revenue Forecast In 2031

USD 1,633.9 Mn

Growth Rate CAGR

CAGR of 11.3% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Mn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Type of Product, Type of Drug Discovery Steps, Type of Therapeutic Area

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Buy 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2510 

Market Dynamics:

Drivers:

The increasing prevalence of chronic diseases like cancer and metabolic disorders has urged a demand for innovative therapies, with peptide-based treatments emerging as promising solutions. Advancements in peptide synthesis techniques, such as PEGylation, and the development of oral formulations have boosted their stability, effectiveness, and patient acceptance. Moreover, substantial investments in research and development by pharmaceutical firms, research institutions, and governments are driving market growth.

Peptide drugs offer targeted and potentially safer options for addressing unmet medical needs across various conditions, because of their ability to selectively target specific biological pathways. Technological progress in computational methods, structural biology, and high-throughput screening has further propelled the discovery and optimization of peptide-based therapeutics, shaping the landscape of the peptide drug market.

Challenges:

The peptide drug discovery market faces significant challenges. Peptides are susceptible to degradation by enzymes, which reduces their effectiveness and shelf life. Their low oral bioavailability necessitates parenteral administration, adding complexity and cost to treatment. Predicting their pharmacokinetics and pharmacodynamics is challenging, hindering optimization for efficacy and safety. Synthesizing and purifying peptides is time-consuming and expensive, limiting production scalability.

Regulatory approval processes are complex and lengthy, with stringent requirements for clinical trials and marketing authorization. The high costs and complexities associated with development make it difficult for companies to realize returns on investment. Despite their potential, these obstacles pose formidable challenges to the widespread adoption of peptide-based therapies in the market.

Regional Trends:

North America stands out as a leading region in the peptide drug discovery market, propelled by several key factors. With its robust healthcare infrastructure, North America boasts advanced medical facilities and a skilled workforce, facilitating the development and commercialization of peptide therapeutics. The region's high-cost environment for peptide medications paradoxically contributes to market growth, as patients recognize and are willing to invest in the efficacy and specificity of these treatments. Moreover, favorable reimbursement regulations ensure widespread access to peptide therapeutics, enhancing patient care management. Additionally, the increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders further fuels demand for peptide drugs in North America

Curious about this latest version of the report? @  https://www.insightaceanalytic.com/enquiry-before-buying/2510 

Recent Developments:

  • In April 2024, PeptiDream Inc., a biopharmaceutical firm in Kanagawa, Japan, is expanding its collaboration with Novartis Pharma AG, based in Switzerland. PeptiDream will use its Peptide Discovery Platform System (PDPS®) to identify and optimize macrocyclic peptides for Novartis. These peptides may be used for radioligand therapies (RLTs) or other therapeutic and diagnostic applications.
  • In June 2023, IRBM, a pioneering contract research organization, has recently inked a fresh deal with Merck & Co. Inc., headquartered in Rahway, NJ, USA, and known as MSD outside the USA and Canada, to extend their partnership in the realm of peptide therapeutics.

Segmentation of Peptide Drug Discovery Market-

By Type of product

  • Synthetic Peptides
  • Biological Peptides
  • Recombinant Peptides
  • Macrocycles Peptides

By Drug discovery steps

  • Target Identification and Validation
  • Hit Identification
  • Lead Generation
  • Lead Optimization

By Therapeutic area

  • Oncological Disorders
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Infectious Disorders
  • Urological Disorders
  • Endocrine Disorders
  • CNS Disorders
  • Other Diseases

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/2510 

Why should buy this report:

  • To receive a comprehensive analysis of the prospects for Peptide Drug Discovery market
  • To receive industry overview and future trends of Peptide Drug Discovery market
  • To analyze the Peptide Drug Discovery market drivers and challenges
  • To get information on the Peptide Drug Discovery market size value (US$ Mn) forecast till 2031
  • Major Investments, Mergers & Acquisition in Peptide Drug Discovery industry

Other Related Reports Published by InsightAce Analytic:

Bioactive Protein and Peptides Market 

Peptide CDMO (Pharmaceutical) Market 

Constrained Peptide Drugs Market

Next Generation Drug Conjugates Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:
InsightAce Analytic PVT. LTD
Tel.: +1 551 226 6109
Email: [email protected]
Follow us on LinkedIn: https://www.linkedin.com/company/insightace-analytic-pvt-ltd/ 

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

SOURCE InsightAce Analytic Pvt. Ltd

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.